| 证券代码 | ADXS.O |
| 证券名称 | Advaxis Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2013-10-17 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Advaxis, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 305 College Road East, Princeton, New Jerseym, USA |
| 成立日期 | 2002-03-01 |
| 董事会主席 | David Sidransky |
| 公司属地 | United States 美国 |
| 公司网址 | www.advaxis.com |
| 电话 | +1 (609) 452-9813 |
| 传真 | - |
| 公司简介 | Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and preclinical development: HPV-associated cancers, neoantigen therapy, hotspot/cancer antigens and prostate cancer. |